Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at UCSF

Sites in San Francisco, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 3:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1396
Shown on this page
12
Current sort
Recently updated
Campus scope
UCSF, San Francisco, CA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within UCSF, San Francisco, CA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 781–792 of 1,396 matching trials with a site at UCSF, San Francisco, CA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 2 Interventional

Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

NCT05389215
Site status not listed — check the official record
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DWN12088, Placebo
Drug
Lead sponsor
Daewoong Pharmaceutical Co. LTD.
Industry
Eligibility
40 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Mesa, Arizona • Phoenix, Arizona • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 27, 2026, 3:33 PM EDT
Active, not recruiting Phase 2 Interventional Results available

CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

NCT04231851
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Interventions
Glasdegib, CPX-351
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 27, 2026, 3:33 PM EDT
Recruiting Phase 3 Interventional

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

NCT06264180
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Melanoma
Interventions
Vusolimogene Oderparepvec, Nivolumab, Nivolumab + Relatlimab, Pembrolizumab, Single-agent chemotherapy
Biological · Drug
Lead sponsor
Replimune, Inc.
Industry
Eligibility
12 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
50
States / cities
Gilbert, Arizona • La Jolla, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 27, 2026, 3:33 PM EDT
Recruiting Not applicable Interventional

Prehab and Creatine/Whey Supplementation in Frailty Among Patients With Cirrhosis

NCT07029243
Status at this site: Recruiting
View directory record Official record
Conditions
Cirrhosis, Frailty, Sarcopenia
Interventions
HEAL-ME digital app, Creatine supplementation, Whey protein supplementation, Placebo
Behavioral · Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 27, 2026, 3:33 PM EDT
Recruiting Not applicable Interventional

Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas

NCT03948490
Status at this site: Recruiting
View directory record Official record
Conditions
Low-grade Glioma
Interventions
ReMind iPad app, Healthy SMS texting, In-person cognitive rehabilitation, Telehealth cognitive rehabilitation
Device · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 27, 2026, 3:33 PM EDT
Recruiting Early Phase 1 Interventional

Probiotic Administration for Adolescent Depression

NCT06898788
Status at this site: Recruiting
View directory record Official record
Conditions
Depression
Interventions
Visbiome, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
15 Years to 24 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 27, 2026, 3:33 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Sodium in the Skin and Atopic Dermatitis

NCT06998446
Status at this site: Recruiting
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 27, 2026, 3:33 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

NCT05286801
Site status not listed — check the official record
View directory record Official record
Conditions
Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma, Malignant Solid Neoplasm, Poorly Differentiated Chordoma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Chordoma, Recurrent Epithelioid Sarcoma, Recurrent Kidney Medullary Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Rhabdoid Tumor, Refractory Atypical Teratoid/Rhabdoid Tumor, Refractory Chordoma, Refractory Epithelioid Sarcoma, Refractory Kidney Medullary Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Rhabdoid Tumor, Rhabdoid Tumor
Interventions
Atezolizumab, Biospecimen Collection, Computed Tomography, Echocardiography Test, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography, Tiragolumab, X-Ray Imaging
Biological · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
35
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 27, 2026, 3:33 PM EDT
Recruiting Not applicable Interventional

Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial

NCT05924477
Status at this site: Recruiting
View directory record Official record
Conditions
Glaucoma
Interventions
Sulcus tube placement, Anterior chamber (AC) tube placement
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
San Francisco, California • Walnut Creek, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 27, 2026, 3:33 PM EDT
Active, not recruiting Phase 2 Interventional

Study of INBRX-109 in Conventional Chondrosarcoma

NCT04950075
Site status not listed — check the official record
View directory record Official record
Conditions
Conventional Chondrosarcoma
Interventions
INBRX-109, Placebo
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
32
States / cities
Phoenix, Arizona • Beverly Hills, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 27, 2026, 3:33 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Glucose Evaluation Through Continuous Glucose Monitors in Polycystic Ovary Syndrome

NCT06050265
Site status not listed — check the official record
View directory record Official record
Conditions
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Dysglycemia, Insulin Resistance
Interventions
DEXCOM Continuous Glucose Monitor (CGM)
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 27, 2026, 3:33 PM EDT
Active, not recruiting Phase 3 Interventional

Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

NCT05248646
Site status not listed — check the official record
View directory record Official record
Conditions
Immunoglobulin A Nephropathy
Interventions
Sibeprenlimab 400 mg, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
54
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 27, 2026, 3:33 PM EDT

About this UCSF institution page

What this page lists
ClinicalTrials.gov records that list UCSF in San Francisco, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by University of California, San Francisco at any site, browse by condition, or browse by U.S. city.